The National Hemophilia Foundation (NHF) in partnership with McMaster University is pleased to announce the publication of an evidence-based clinical practice guideline on Care Models for Hemophilia Management. The NHF-McMaster Guideline was developed to identify best practices in hemophilia care delivery to optimize outcomes for people living with hemophilia across the United States. The Guideline concludes that the integrated care model be used for people with hemophilia and especially for people with hemophilia with inhibitors or at high risk of inhibitors for optimal care based on the certainty of the available evidence.
A number of national and international guidance documents have supported integrated care as the optimal model of care for people with hemophilia. However, the effects of integrated care on patient-important outcomes had not previously been systematically synthesized or compared to alternative models. This guideline addresses these issues and identifies areas for further research to evaluate the optimal composition of the integrated care delivery model and its impact on specific patient outcomes.
The Guideline was developed foremost for persons living with hemophilia and for providers of hemophilia care. In addition, the guideline is meant to be a resource for hospitals and healthcare systems, Federal and State programs and policy makers, private and public insurers, and other professionals in the health sector who are responsible for developing and implementing strategies to care for individuals with hemophilia and other bleeding disorders at the national, regional and state levels.
NHF sought the expertise of McMaster University, internationally recognized for its work in this field, to assure that the methods used to develop the guidelines adhered to the principles promoted by National Guideline Clearinghouse and the Institute of Medicine. The Guideline was developed to identify best practices in hemophilia care delivery to optimize outcomes for people living with hemophilia across the United States.
The Guideline has been endorsed by the World Federation of Hemophilia, the American Society of Hematology and the International Society on Thrombosis and Haemostasis.
Read the Executive Summary of the Guideline.
A detailed version of this guideline, as well as supplementary materials have been published in the July 2016, Vol. 22, Supplement 3 issue of the journal Haemophilia, available online at: http://onlinelibrary.wiley.com/doi/10.1111/hae.2016.22.issue-S3/issuetoc
